# Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile

> **NCT05593042** · PHASE2 · COMPLETED · sponsor: **Pontificia Universidad Catolica de Chile** · enrollment: 551 (actual)

## Conditions studied

- COVID-19
- Vaccines

## Interventions

- **BIOLOGICAL:** CoronaVac®
- **BIOLOGICAL:** Omicron Vaccine
- **BIOLOGICAL:** Trivalent Vaccine

## Key facts

- **NCT ID:** NCT05593042
- **Lead sponsor:** Pontificia Universidad Catolica de Chile
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-28
- **Primary completion:** 2023-10-26
- **Final completion:** 2023-10-26
- **Target enrollment:** 551 (ACTUAL)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05593042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05593042, "Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05593042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*